FDA grants IND clearance for Allay’s trial of post-surgical pain treatment

The US Food and Drug Administration (FDA) has granted clearance to Allay Therapeutics’ investigational new drug (IND) application to initiate a Phase IIb clinical trial of ATX101, aimed at alleviating post-surgical pain in patients undergoing total knee replacement surgery.